Clinical trials: Nicotinamide
COVID-19 Infection
Study to Evaluate the Effect of Nicotinamide Mononucleotide (NMN) As an Adjuvant to Standard of Care (SOC) On Fatigue Associated With COVID-19 Infection
A Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Effect of Nicotinamide Mononucleotide (NMN) As an Adjuvant to Standard of Care (SOC) On Fatigue Associated with COVID-19 Infection
- Trial name
- NCT05175768
- Testing
- Nicotinamide Mononucleotide, Nicotinamide Mononucleotide with L-Leucine
- Where
- 12 sites in India
- Volunteers
- 69 people
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Chronic Kidney Disease, Hemodialysis
Nicotinamide in Hemodialysis Patients With Hyperphosphatemia
Study hypothesis: Nicotinamide inhibits gastrointestinal phosphate absorption and serum phosphate levels of dialysis patients in a dose dependent manner.
- Conditions
- Chronic Kidney Disease, Hemodialysis, Hyperphosphatemia
- Trial name
- DONATO (NCT01200784)
- Testing
- Nicotinamide
- Where
- 36 sites in Germany
- Volunteers
- 252 people
- Sponsor
- Medice Arzneimittel Pütter GmbH & Co KG
Healthy
Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program
A single-center, randomized, placebo-controlled study in community dwelling, healthy, regularly exercising, highly physically fit men and women, 19 to 40 years.
- Trial name
- NCT05878119
- Testing
- Investigational Product - MIB 626, Standardized, progressive, high intensity, multidimensional exercise, Usual Physical Activity
- Where
- United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Metro International Biotech, LLC
Dyslipidemia
A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)
This study will evaluate the efficacy of laropiprant (LRPT) to reduce flushing symptoms beyond 6 months and will measure the impact of withdrawal of laropiprant in patients following 20 weeks of stable maintenance therapy.
- Trial name
- NCT00961636
- Testing
- ER niacin (+) laropiprant (ERN/LRPT), Extended-release niacin (ERN)
- Volunteers
- 1,152 people
- Sponsor
- Merck Sharp & Dohme LLC
Increase in Blood Levels of Nicotinamide Adenine Dinucleotide (NAD+)
Open-label Study to Assess Increasing Levels of NAD+(Nicotinamide Adenine Dinucleotide)
The purpose of this study is to assess an effective single oral supplement or combination of oral supplements for increasing whole blood NAD+ levels.
- Trial name
- NCT03707652
- Testing
- Oral supplement A, Oral supplement B, Oral supplement C
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Supplement Formulators, Inc.
Skin Care
A Study to Evaluate of Cosmetic Benefit of a Moisturising Cream in People With Blemish Prone Skin
This study is designed to evaluate the cosmetic benefit provided by twice daily application of a developmental moisturising cream with niacinamide for 8 weeks in healthy female participants with sensitive, oily, blemish-prone…
- Trial name
- NCT03093181
- Testing
- Washout / Standard Cleanser, Test product, Positive control cleanser
- Where
- Brazil
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Skin Aging on Face, Skin Care Dermocosmetics
Efficacy of Topical Niacinamide Riboside on the Signs of Facial Skin Aging
Niacinamide riboside (topical NR, also known as nicotinamide riboside) is an endogenous compound and a precursor (building block) to the essential cellular co-enzyme, nicotinamide adenine dinucleotide (NAD+).
- Conditions
- Skin Aging on Face, Skin Care Dermocosmetics, Skin Care, Fine Lines and Wrinkles
- Trial name
- NR-RADIANCE (NCT07774000)
- Testing
- Topical niacinamide riboside
- Where
- South Africa
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- ChromaDex, Inc.
Dyslipidemia
MK0524B Bioequivalence Study (0524B-070)
This study will evaluate: 1. the bioequivalence of simvastatin and simvastatin acid following dose of simvastatin (ZOCOR™) given together with one tablet of MK0524A or as a component of the triple combination tablet MK0524B. 2.
- Trial name
- NCT00943124
- Testing
- MK0524B (ER niacin (+) laropiprant (+) simvastatin), MK0524A (ER niacin + laropiprant), Simvastatin
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia
Safety & Efficacy of a Combination Niacin ER/Simvastatin in Patients With Dyslipidemia: A Dose-Ranging Study - SEACOAST
The purpose of this study is to compare the effectiveness and safety of different doses of Niacin ER/Simvastatin (NS), in subjects with elevated fat levels in their blood (dyslipidemia).
- Trial name
- NCT00082251
- Testing
- Niacin extended release and simvastatin tablets
- Sponsor
- Kos Pharmaceuticals
Flushing
MK0524A Phase IIb Study (0524A-011)(COMPLETED)
Part A: This study will determine that MK0524 is well tolerated and does not effect lipids and blood glucose when given alone. Part B: Determine dose ranges for MK0524 and MK0524 plus Niaspan(R) on the effects of lipids and blood…
- Trial name
- NCT00536237
- Testing
- Comparator: niacin / Duration of Treatment: 17 Weeks, MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks
- Volunteers
- 154 people
- Sponsor
- Merck Sharp & Dohme LLC
Dyslipidemia, Coronary Heart Disease
Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL
The purpose of this study is to evaluate the effectiveness of first-line treatment using Niaspan (an extended release version of niacin) and statins versus other drugs that lower lipid levels, in subjects with elevated fat levels…
- Conditions
- Dyslipidemia, Coronary Heart Disease, Atherosclerosis, Stroke
- Trial name
- NCT00079638
- Testing
- Niacin, Atorvastatin, Simvastatin
- Volunteers
- 300 people
- Sponsor
- Kos Pharmaceuticals
Pharmacokinetics
A Study of the Pharmacokinetics of Three Dosages of Niagen in Healthy Subjects
The purpose of this study in to analyse the way in which the body processes Niagen (nicotinamide riboside) in healthy people. Blood and urine samples from subjects who are given a dose of Niagen will be analyzed for metabolites…
- Trial name
- 14NBHC (NCT02191462)
- Testing
- Niagen 100mg, Niagen 300mg, Niagen 1000mg
- Where
- Canada
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- KGK Science Inc.
Healthy
Safety and Efficacy of Topical Cream for Post-inflammatory Hyperpigmentation Skin Among Malaysians
This study was conducted to determine safety and efficacy of topically applied cream containing combination of niacinamide, arbutin, Scutellaria Baicalensis Root Extract, Centella Asiatica Extract and Camellia Sinensis Leaf…
- Trial name
- NCT05986123
- Testing
- Topical cream Z for PIH
- Where
- Malaysia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- USMARI Research & Innovation Centre
Primary Hypercholesterolemia, Mixed Dyslipidemia
Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067)
This is a 12-Week clinical trial in patients with Primary hypercholesterolemia or mixed dyslipidemia to study the effects of ER niacin/laropiprant on lipids.
- Trial name
- NCT00479388
- Testing
- Comparator: simvastatin, niacin (+) laropiprant, Comparator: atorvastatin calcium
- Volunteers
- 1,216 people
- Sponsor
- Merck Sharp & Dohme LLC
Muscle Injury
Nicotinamide (NAM) and Pyridoxine (vitamin B6) on Muscle Regeneration ("Satellite-01 Study").
Assessment of safety and efficacy of NAM/B6 oral administration on the amplification and commitment of satellite cells after a muscle injury
- Trial name
- NCT04874662
- Testing
- NAM/B6
- Where
- Denmark
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Hypercholesterolemia
A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)
The purpose of this study is to evaluate the potential effects of ER niacin/laropiprant, ER niacin, laropiprant, and placebo over the course of seven days on urinary levels of a metabolite of thromboxane A2 (TxA2), as a marker of…
- Trial name
- NCT00769132
- Testing
- Comparator: niacin + laropiprant, Comparator: niacin, Comparator: laropiprant
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia, Hyperlipidemia
Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)
This is a 16-week clinical trial in lipid clinic patients for whom niacin therapy is appropriate to evaluate the tolerability of MK0524A versus niacin extended-release.
- Trial name
- NCT00378833
- Testing
- niacin (+) laropiprant, niacin
- Volunteers
- 1,300 people
- Sponsor
- Merck Sharp & Dohme LLC
Flushing
Endpoint Validation Study (0524A-015)
To determine the most effective daily dose of MK0524A when compared with placebo after the 8-week treatment period for Niacin Induce Flushing (NIF).
- Trial name
- NCT00533676
- Testing
- MK0524A, /Duration of Treatment : 8 Weeks
- Volunteers
- 165 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia, Familial, Heterozygous Familial Hypercholesterolemia
A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)
The purpose of this study is to determine the pharmacokinetics of laropiprant following administration of a single dose of 1 (Panel A) and 2 (Panel B) combination tablets of MK-0524A in adolescents with heterozygous familial…
- Trial name
- NCT01583647
- Testing
- MK-0524A
- Volunteers
- 10 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Subjects, Dyslipidaemias
A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers
To test the ability of GSK256073 to block niacin-induced flushing when GSK256073 and niacin are co-administered as single doses to HVTs.
- Trial name
- NCT00608699
- Testing
- GSK256073A tablets + IR niacin tablets
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline